Business

Know the Business

Lyka Labs is a ₹214 Cr market-cap, 50-year-old Indian pharma formulator built around two hard-to-do dosage forms — lyophilized injectables and topical formulations — run out of a single Ankleshwar plant, with Ipca Laboratories as the 58%-owning promoter-cum-anchor customer. Revenue is small (₹138 Cr in FY25) and lumpy, two customers drive ~36% of sales, and the one standout year (FY22, ₹101 Cr EBITDA, 52% OPM) was almost certainly a related-party mix event, not a repeatable baseline. The market is pricing a turnaround; what actually matters is whether Ipca-linked volumes and the freshly-capitalized Lyophilization Phase-I line convert into durable operating cash — which through FY25 they have not (FCF was negative ₹7 Cr and ₹10 Cr in FY24 and FY25).

**The one thing to internalize:** this is not a typical pharma formulator. It is effectively a captive/contract manufacturer for Ipca (promoter) plus a tiny branded domestic book plus a sub-scale export arm. Read every metric through that lens.

How This Business Actually Works

The economic engine is a single plant making two dosage-form specialties, sold through three distinct channels. Each channel has a completely different margin and capital profile.

No Results

Where profit actually leaks in or out: the bottleneck is plant utilization, not demand. Fixed costs (depreciation, plant staff, rent) are ~₹70-80 Cr; above that breakeven revenue, incremental sales drop to the bottom line at very high margins. This is exactly what FY22 showed — revenue doubled to ₹194 Cr, OPM hit 52%, net profit flipped to ₹38 Cr. But the same year the related-party note shows ₹21 Cr of sales to Ipca and an unusual product mix; that year has never repeated. Below ~₹120 Cr of revenue, this P&L goes back to loss.

Bargaining power cuts against Lyka: it buys APIs in a commoditized market, sells into a fragmented domestic generics market where "competition from small manufacturers" is called out in the FY25 AGM notice as the reason margins stay under pressure, and has one related-party anchor customer that owns 58% of the equity. Pricing power is structurally weak.

The Playing Field

Lyka is a bottom-decile scale operator in a sector where scale is the moat. Peers that look even remotely comparable are 5–150× larger in revenue.

No Results

What the peer set reveals. The companies that actually earn high returns in this space do one of two things: (a) own branded franchises in hard-to-replicate geographies (Caplin in Latam/Africa), or (b) run large complex-injectable / export platforms at scale (Marksans, Shilpa). Lyka does neither. It shares the "small domestic formulator" profile with Jagsonpal/Makers — but without Jagsonpal's 40-year brand book. Windlas shows what a disciplined CDMO-for-India-pharma model looks like at scale: ₹720 Cr revenue, 17% ROCE, positive FCF. Lyka has the lyophilization know-how to plausibly move toward that archetype — but it has been "about to" for a decade and the export book keeps missing tenders.

**"Good" in this industry means ROCE > 18% and FCF/EBITDA > 60% through a cycle.** Lyka's 10-year average ROCE is roughly 4% and cumulative 10-year FCF is negative. The peer table is not a valuation screen — it's a reminder that micro-cap Indian pharma formulators with the wrong scale almost never earn their cost of capital.

Is This Business Cyclical?

It is not macro-cyclical in the usual sense — generics demand is defensive — but Lyka's P&L is extraordinarily mix- and utilization-cyclical. The swing factors are (1) single large contract-manufacturing orders from Ipca, (2) timing of international government tenders, and (3) write-downs/one-offs when things go wrong.

The three concrete "downturns" on this chart:

FY18–FY20 collapse. Revenue halved from ₹110 Cr to ₹60 Cr; equity reserves went negative (-₹43 Cr by FY20); the company was recapitalized by Ipca via preferential issue. This is the failure mode for a sub-scale single-plant formulator — one product ramp-down or lost customer and the plant goes under breakeven.
FY22 spike. The outlier year. Reported 52% OPM alongside an unusually large related-party revenue book and a jump in "sale of goods" to Ipca. Do not extrapolate anything from this year; it is the single data point that inflates every trailing average.
FY24 post-spike normalization. Revenue back to ₹111 Cr, net profit of ₹(3) Cr despite a reported ₹182% effective tax bounce. Shows how quickly profitability vanishes when the FY22-style mix doesn't repeat.

**Where the real cyclicality hits: working capital.** Debtor days have moved from 35 in FY22 → 79 → 89 → 114 in FY25. Cash conversion cycle flipped from minus 63 days to plus 97 days. That swing consumed the entire reported P&L profit — FCF was negative ₹7 Cr in FY24 and negative ₹10 Cr in FY25 despite a return to book profit. For a ₹138 Cr business, that is the single most important number on this page.

The Metrics That Actually Matter

Forget P/E — there isn't a stable E. For Lyka, these five metrics, in this order, explain the stock:

No Results

Why these beat the usual ratios. ROE and OPM cherry-pick FY22 into every trailing window, which is why screens call Lyka "turnaround with ROE 9%." They miss that (a) the profit is not cashing, (b) customer concentration is rising not falling, and (c) the growth is front-loaded on one anchor customer whose balance sheet isn't under discussion. Watch the four metrics above for three quarters in a row before believing any rerate.

What I'd Tell a Young Analyst

Do not value this on earnings. Value it on plant utilization times normalized contribution margin, and haircut for related-party concentration. The bull case is real but narrow: if the new Lyophilization Phase-I line ramps and Ipca migrates more volume in (which it logically would, given the 58% stake and the ₹50 Cr annual RPT ceiling just approved), revenue could step to ₹200-250 Cr with 18-22% OPM. That is ₹40 Cr EBITDA on a ₹214 Cr EV — cheap. But you only earn that re-rate if FCF turns positive for four consecutive quarters and debtor days compress back to 60. Neither has started.

Three things would change the thesis — watch in this order:

Cash conversion. If debtor days go above 130, or CCC above 110, the story is broken regardless of reported profit. Conversely, a return to sub-60 debtor days alongside revenue growth would be the first real bullish signal in a decade.
Ipca disclosure patterns. Related-party sales crossing 25-30% of revenue, or the Lyka Exports amalgamation (effective 8 April 2026) being followed by further group-consolidation steps, would tell you the business is being quietly restructured into an Ipca captive — re-rate that against Ipca's own comps, not Lyka's.
A second anchor customer. The filings note "2 customers >10% of revenue" for the first time in FY25. If the non-Ipca name disclosed becomes a multi-year contract (especially an EU/US injectables account), the thesis flips from captive-cyclical to genuine CDMO.

What the market is probably over-weighting: the FY22 profit number, the "debt reduced from ₹163 Cr to ₹32 Cr" narrative (it reduced because Ipca paid ₹34 Cr of equity capital and ₹3,367 Lakh of share premium, not because the business generated cash), and the 9.3% ROE (mechanical bounce off a tiny equity base plus a very low-tax FY25 comparison year).

What the market is probably under-weighting: the quality of the reported FY25 profit (OCF/PAT of 0.25×), the fact that Q2 FY26 already printed an operating loss (Sep 2025: −₹2.5 Cr OPM), and the structural reality that Lyka without Ipca is a sub-breakeven business.